Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 3/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.36 |
| ▸ | CYP1A1 | P04798 | 5/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7981839 | 0.74 | LMNA (0.57) | MAOBALDH1A1KDM4EHSD17B10CA12 | |
| SCHEMBL21224661 | 0.74 | ALDH1A1 (0.56) | MAOBMAOAALDH1A1CYP3A4KDM4E | |
| SCHEMBL118769 | 0.74 | SLC22A12 (0.40) | MAOBPIM1ESR1ESR2MAOA | |
| SCHEMBL120165 | 0.74 | ERN1 (0.44) | MAOBPIM1ALDH1A1CYP3A4KDM4E | |
| SCHEMBL118295 | 0.74 | SLC22A12 (0.42) | MAOBPIM1ESR1ESR2MAOA | |
| SCHEMBL21230502 | 0.74 | MAOB (0.39) | MAOBPIM1ESR1ESR2ALDH1A1 | |
| SCHEMBL22960809 | 0.73 | LMNA (0.63) | PIM1ALDH1A1CYP3A4KDM4EHPGD | |
| SCHEMBL1428881 | 0.71 | ESR1 (0.56) | MAOBESR1ESR2MAOAALDH1A1 | |
| SCHEMBL16623261 | 0.70 | SLC22A12 (0.40) | MAOBPIM1ESR1ESR2MAOA | |
| SCHEMBL28491738 | 0.69 | PIM1 (0.43) | PIM1ALDH1A1CYP3A4KDM4ECYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9919060-B2 | Treatment or prophylaxis of proliferative conditions | UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) | 2018-03-20 | — | — | US | claimed |
| US-11760773-B2 | Small molecule drug conjugates of gemcitabine monophosphate | MAVERIX ONCOLOGY, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20210380626-A1 | NOVEL SMALL MOLECULE DRUG CONJUGATES OF GEMCITABINE DERIVATIVES | MAVERIX ONCOLOGY, INC. | 2021-12-09 | — | — | US | disclosed |
| US-20210040136-A1 | SMALL MOLECULE DRUG CONJUGATES OF GEMCITABINE MONOPHOSPHATE | MAVERIX ONCOLOGY, INC. | 2021-02-11 | — | — | US | disclosed |
| CN-112135635-A | Novel small molecule drug conjugate of gemcitabine derivative | 马福瑞克斯肿瘤学股份有限公司 | 2020-12-25 | — | — | CN | disclosed |
| CN-112135634-A | Small molecule drug conjugate of gemcitabine monophosphate | 马福瑞克斯肿瘤学股份有限公司 | 2020-12-25 | — | — | CN | disclosed |
| EP-3746134-A1 | SMALL MOLECULE DRUG CONJUGATES OF GEMCITABINE MONOPHOSPHATE | MAVERIX ONCOLOGY, INC. (US) | 2020-12-09 | — | — | EP | disclosed |
| EP-3746133-A1 | NOVEL SMALL MOLECULE DRUG CONJUGATES OF GEMCITABINE DERIVATIVES | MAVERIX ONCOLOGY, INC. (US) | 2020-12-09 | — | — | EP | disclosed |
| WO-2019152955-A9 | SMALL MOLECULE DRUG CONJUGATES OF GEMCITABINE MONOPHOSPHATE | EVERETT STEVEN ALBERT (US) | 2020-08-13 | — | — | WO | disclosed |
| WO-2019152911-A1 | NOVEL SMALL MOLECULE DRUG CONJUGATES OF GEMCITABINE DERIVATIVES | EVERETT STEVEN ALBERT (US) | 2019-08-08 | — | — | WO | disclosed |
| WO-2019152955-A1 | SMALL MOLECULE DRUG CONJUGATES OF GEMCITABINE MONOPHOSPHATE | EVERETT STEVEN ALBERT (US) | 2019-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210380626-A1 | NOVEL SMALL MOLECULE DRUG CONJUGATES OF GEMCITABINE DERIVATIVES | ZYX, KRAS, SLC7A5 | MAOB 4134/4885PIM1 3328/4885ESR1 3741/4885 |
| US-11760773-B2 | Small molecule drug conjugates of gemcitabine monophosphate | ZYX, SLC7A5, GMPS | MAOB 3534/4885PIM1 2693/4885ESR1 4397/4885 |
| US-20210040136-A1 | SMALL MOLECULE DRUG CONJUGATES OF GEMCITABINE MONOPHOSPHATE | ZYX, SLC7A5, GMPS | MAOB 3447/4885PIM1 2745/4885ESR1 4400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.